Steakholder Foods Ltd. Q4 FY2021 earnings call

• In March 2021, listed on NASDAQ and raised $28M via IPO, delisted from Tel Aviv Stock Exchange in August. - Partnered with Blue Sound Waves Collective in October 2021 to support go-to-market. - Acquired Peace of Meat in February 2021, broadening tech to poultry. - Announced pilot plant in Belgium for cultured fat production in May 2021, with a term sheet signed for it. - Manufactured 700g cultured chicken fat in Sept 2021, had tasting events in Oct, 3D printed 100g steak in Dec. - Opened California office in 2022 for R&D, investor relations, and business development. - R&D expenses in 2021 totaled $7.6M vs $2.5M in 2020, cash and equivalents at $19.2M as of year end 2021.

No detailed product segment financial performance with absolute revenue and contribution % provided in the transcript.

• Continue R&D efforts to launch new hybrid products in 2022. - Push for regulatory approvals in key target markets. - Strengthen market position in the US. - Aim to sign collaboration agreements with industry players. - Expect R&D expenses to continue in line with recent quarters in 2022.

• Uncertainty in regulatory approval timelines (could be longer or shorter than expected). - Dependence on successful execution of R&D and partnerships.

Q: Sara Welford asked about R&D expenses going forward and if hybrid products will come to market sooner than pure cultured meat.

A: Guy Hefer said R&D expenses likely in line with recent quarters; Arik Kaufman stated hybrid products could hit market sooner than purely printed steak.

Q: Sara Welford followed up on regulatory approval timeline.

A: Arik Kaufman said approximately 2 years in US, EU may take longer, smaller markets like Singapore earlier.

Q: Ben Haynor asked about proportion of cultured meat needed in hybrid offerings, location of US headquarters, and other early adopter markets.

A: Arik Kaufman discussed hybrid product variability, talent and incentives considered for US locations, and Asian markets like Thailand and Japan as potential early adopters.

Q: Jennifer Scutti asked about US regulatory process steps.

A: Arik Kaufman explained FDA and USDA regulation in the US, noting process is unfolding with uncertain timeline.